[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy-induced-systolic-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy-induced-systolic-dysfunction":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100497389",false,"NCT05756608","Fibrosis in Chronic and Delayed Myocardial Infarction","FCDMI","Inclusion Criteria:\n\nCohort 1(Aortic stenosis):\n\n* Male or female above the age of 50 years old\n* Provision of informed consent prior to any study specific procedures\n* 25 patients with symptomatic severe aortic stenosis (peak velocity \\>4.0 m\u002Fs)\n* 25 patients with moderate aortic stenosis (peak velocity 3.0-4.0 m\u002Fs)\n* 10 patients with mild aortic stenosis (peak velocity 2.6-2.9 m\u002Fs)\n* 10 patients with aortic sclerosis (tri-leaflet thickened aortic valve with no obstruction of ventricular outflow)\n* 10 healthy volunteers (no other significant co-morbidities, as assessed by the study PI)\n\nCohort 2 (Chemotherapy-induced cardiotoxicity):\n\n* Male or female over the age of 35 years with evidence of cardiotoxicity on cardiac MRI (performed as part of the Cardiac care study), at least 1 year after anthracycline treatment.\n* 10 patients over the age of 35 years (male or females) without evidence of fibrosis on their 1-year scan after anthracycline treatment.\n* 10 healthy volunteers (\\>35 years of age) with no significant co-morbidities, as assessed by the study PI.\n* Provision of informed consent prior to any study specific procedures\n\nCohort 3 (Carcinoid syndrome):\n\n* 30 patients with carcinoid syndrome (with or without cardiac involvement), over the age of 35 years, diagnosed as per consensus guidelines\n* Provision of informed consent prior to any study specific procedures\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent.\n* History of claustrophobia or feeling of inability to tolerate supine position for the MRI scans.\n* Impaired renal function with eGFR of \\\u003C30 mL\u002Fmin\u002F1.73m2.\n* Women who are pregnant or breastfeeding.\n* Contrast allergy\n* Contraindication to cardiac MRI (e.g. metallic implant or severe claustrophobia)\n* Recent myocardial infarction, other known causes of cardiomyopathy\u002Fcardiac fibrosis.",true,"ALL","40 Years","90 Years",{"count":20,"type":21},180,"ESTIMATED","OBSERVATIONAL","In this study the investigators aim to examine the role that fibrosis plays in heart conditions such as aortic stenosis , chemotherapy-induced cardiotoxicity and carcinoid syndrome . Fibrosis is a common final result following any injury to the heart muscle and the investigators aim to identify this process early and in its active state. This will be examined by using a radiotracer 68Ga-FAPI or 18F-AlF-FAPI and PET-MRI or PET-CT.",[25,26,27],"Aortic Stenosis","Chemotherapy Induced Systolic Dysfunction","Carcinoid Syndrome","RECRUITING","2026-01-08",{"date":31,"type":32},"2026-01-09","ACTUAL",{"date":34,"type":32},"2022-11-10",{"date":36,"type":21},"2028-08-31",{"name":38,"class":39},"University of Edinburgh","OTHER",""]